Xenetic Biosciences, Inc. (XBIO)
1.72
-0.21
(-10.88%)
USD |
NASDAQ |
Oct 23, 16:00
1.71
-0.01
(-0.58%)
After-Hours: 20:00
Xenetic Biosciences Enterprise Value : -2.442M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | -2.442M |
| October 22, 2026 | -1.949M |
| October 21, 2026 | -1.738M |
| October 20, 2026 | -1.785M |
| October 19, 2026 | -1.949M |
| October 16, 2026 | -1.809M |
| October 15, 2026 | -1.762M |
| October 14, 2026 | -1.551M |
| October 13, 2026 | -1.551M |
| October 12, 2026 | -1.504M |
| October 09, 2026 | -1.481M |
| October 08, 2026 | -1.504M |
| October 07, 2026 | -1.293M |
| October 06, 2026 | -1.504M |
| October 05, 2026 | -1.317M |
| October 02, 2026 | -1.223M |
| October 01, 2026 | -1.223M |
| September 30, 2026 | -1.036M |
| September 29, 2026 | -1.176M |
| September 28, 2026 | -1.012M |
| September 25, 2026 | -0.8716M |
| September 24, 2026 | -0.6841M |
| September 23, 2026 | -0.5669M |
| September 22, 2026 | -0.4498M |
| September 21, 2026 | 0.5344M |
| Date | Value |
|---|---|
| September 18, 2026 | 0.0189M |
| September 17, 2026 | -0.7075M |
| September 16, 2026 | -1.340M |
| September 15, 2026 | 3.534M |
| September 14, 2026 | 3.674M |
| September 11, 2026 | 2.667M |
| September 10, 2026 | 3.065M |
| September 09, 2026 | 3.405M |
| September 08, 2026 | 3.557M |
| September 04, 2026 | 4.471M |
| September 03, 2026 | 4.377M |
| September 02, 2026 | 3.487M |
| September 01, 2026 | 3.440M |
| August 31, 2026 | 3.346M |
| August 28, 2026 | 2.854M |
| August 27, 2026 | 2.831M |
| August 26, 2026 | 2.573M |
| August 25, 2026 | 2.479M |
| August 24, 2026 | 2.456M |
| August 21, 2026 | 1.940M |
| August 20, 2026 | 1.472M |
| August 19, 2026 | 1.401M |
| August 18, 2026 | 1.144M |
| August 17, 2026 | 1.167M |
| August 14, 2026 | 1.214M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.9297M |
| Revenue (Quarterly) | 0.6606M |
| Total Expenses (Quarterly) | 1.590M |
| EPS Diluted (Quarterly) | -0.4052 |
| Profit Margin (Quarterly) | -140.7% |
| Earnings Yield | -69.06% |
| Normalized Earnings Yield | -69.06 |